Quick Answer
Crinetics Pharmaceuticals, Inc. reported Cash and Equivalents of $101.54 million for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $101.54M | -61.6% |
| 2024 | $264.55M | +381.9% |
| 2023 | $54.90M | +68.0% |
| 2022 | $32.67M | -83.7% |
| 2021 | $200.69M | +115.6% |
| 2020 | $93.09M | +130.8% |
| 2019 | $40.33M | -10.3% |
| 2018 | $44.97M | +216.9% |
| 2017 | $14.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $110.90M | -65.0% | +106.4% |
| June 30, 2025 | $53.73M | -82.2% | -43.2% |
| March 31, 2025 | $94.57M | -76.1% | -64.3% |
| December 31, 2024 | $264.55M | +381.9% | -16.6% |
| September 30, 2024 | $317.27M | +122.2% | +5.0% |
| June 30, 2024 | $302.16M | +663.9% | -23.7% |
| March 31, 2024 | $395.92M | +861.1% | +621.2% |
| December 31, 2023 | $54.90M | +68.0% | -61.6% |
- Crinetics Pharmaceuticals, Inc. showed a decrease of -61.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Crinetics Pharmaceuticals, Inc.’s cash and equivalents has grown by 615.4% (from $14.19 million to $101.54 million).
- The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: